DK2573073T3 - Pyrazolquinolinonderivater, deres fremstilling og terapeutisk anvendelse deraf - Google Patents

Pyrazolquinolinonderivater, deres fremstilling og terapeutisk anvendelse deraf Download PDF

Info

Publication number
DK2573073T3
DK2573073T3 DK11306217.8T DK11306217T DK2573073T3 DK 2573073 T3 DK2573073 T3 DK 2573073T3 DK 11306217 T DK11306217 T DK 11306217T DK 2573073 T3 DK2573073 T3 DK 2573073T3
Authority
DK
Denmark
Prior art keywords
dihydro
compound
quinolin
pyrazole
trifluoroethyl
Prior art date
Application number
DK11306217.8T
Other languages
English (en)
Inventor
Alexandre Benazet
Olivier Duclos
Nathalie Guillo
Gilbert Lassalle
Karim Macary
Valérie Viv
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2573073T3 publication Critical patent/DK2573073T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/62—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (14)

1. Forbindelse, der svarer til formel (I):
(I) hvori: RI er: • -(C1-C4)alkyl • -(C1-C4)haloalkyl R2 er: • en gruppe:
• en gruppe:
• en gruppe: -A-X R3 er: • -H • halogen • -(C1-C6)alkyl • en cyanogruppe • -co2h • -CONH2 A er: • en aryl- eller heteroarylgruppe X er fraværende eller er: • halogen • en cyanogruppe • en oxogruppe • - (CH2) nOH • - (C1-C6)haloalkyl • -(C1-C6)alkyl • -(C1-C6)alkoxy • -(CH2)n-aryl • -CHOH-aryl • heterocyclyl • heteroaryl • -(C1-C6)alkylheterocyclyl • -(C1-C6)alkylheteroaryl • -(C1-C6)alkyl-COORa • -(C1-C6)alkyl-NRaRb • -heteroaryl-(CH2)n-NRaRb • -(CH2)n-NRa-C(0)-Rb • -NRaRb • -NRa-(CH2)n-O-Rb • -NRa-heterocyclyl • -NRa-aryl • -NRa-C(0)-(CH2)n-NRaRb • -NRa-C(0)-aryl • -NRaC(0)-(C1-C6)alkyl • -NRa-C(0)-(C1-C6)alkylaryl • -NRa-C(0)-(CH2)n-O-Rb • -NRa-S02-(CH2)n-aryl • -NRa-S02-(CH2)n-NRaRb • -NRa-S02-Rb • -NRa-S02-aryl-0-aryl • -NRa-S02-aryl-(CH2)n-NRb-C(0)-Rb • -COORa • -CONRaRb • -C(0)-NRa-(CH2)n-O-Rb • -C(0)-NRa-aryl-C(0)-NRaRb • -C(O)-NRa-(CH2)n-NRaRb • -C(O)-NRa-(CH2)n-heteroaryl • -O-(CH2)n-NRaRb • -O-heterocyclyl • -CO-heterocyclyl • -CO-heteroaryl • -S02NRaRb • -S02-heterocyclyl Ra og Rb uafhængigt er: • -H • -(C1-C6)alkyl n er 0, 1, 2 eller 3 i form af basen eller af et syreadditionssalt og også i hydratform.
2. Forbindelse med formel (I) ifølge krav 1, der er kendetegnet ved, at R3 er H eller et halogen, mere fortrinsvis chlor; i form af basen eller af et syreadditionssalt og også i hydratform.
3. Forbindelse med formel (I) ifølge det ene eller det andet af kravene 1 og 2, der er kendetegnet ved, at RI er en ethyl eller en trif luorethyl; i form af basen eller af et syreadditionssalt og også i hydratform.
4. Forbindelse med formel (I) ifølge et af kravene 1 til 3, der er kendetegnet ved, at R2 er en gruppe -A-X med A, som er en aryl- eller heteroarylgruppe, og X, som er fraværende eller er en heterocyclyl, NRaRb, (C1-C6)alkyl, et halogen, mere fortrinsvis chlor eller fluor, en cyanogruppe, NRa-S02-Rb, CO-heterocyclyl; i form af basen eller af et syreadditionssalt og også i hydratform.
5. Forbindelse med formel (I) ifølge et hvilket som helst af ovennævnte krav, der er udvalgt blandt følgende forbindelser: - forbindelse 1: 7-(pyrid-2-yl)-5-(2,2,2-trifluorethyl)-1,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 2: 7-(2-aminopyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 3: 7-(2-fluorphenyl)-5-(2,2,2-trifluorethyl)- 1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 4: 5-ethyl-7-pyrid-2-yl-l,5-dihydro-4H- pyrazol[4,3-c]quinolin-4-on; - forbindelse 5: 5-ethyl-7-(4-fluorphenyl) -2,5-dihydro-4tf- pyrazol[4,3-c]quinolin-4-on; - forbindelse 6: 7-(pyrid-4-yl)-5-(2,2,2-trifluorethyl)-1,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 7: 5-ethyl-7-pyrid-4-yl-l,5-dihydro-4H- pyrazol[4,3-c]quinolin-4-on; - forbindelse 8: 7-(2-dimethylaminophenyl)-5-ethyl-l,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 9: N-(3-dimethylaminopropyl)-4-(5-ethyl-4-oxo- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl)benzamid; - forbindelse 10: 5-ethyl-7-(4-piperazin-l-ylphenyl)-1,5- dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 11: 5-ethyl-7-[4-(4-methylpiperazin-l- yl)phenyl] -1,5-dihydro-4 Ji-pyrazol [4,3-c] quinolin-4-on; - forbindelse 12: 7-[2-(morpholin-4-ylcarbonyl)phenyl]-5- (2,2,2-trif luorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 13: N-(2-dimethylaminoethyl)-4-(5-ethyl-4-oxo- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl)benzamid; - forbindelse 14: 7-(2-morpholin-4-ylphenyl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 15: 7-[4-(1-dimethylaminoethyl)phenyl]-5-ethyl- 1.5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 16: 7-(2-morpholin-4-ylmethylpheriyl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 17: 5-ethyl-7-(2-morpholin-4-ylmethylphenyl)- 1.5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 18: 5-ethyl-7-[4-(piperazin-l-carbonyl)phenyl]- 1.5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 19: 7 -[4-(4-methylpiperazin-l-yl) phenyl]-5-(2,2,2-trif luorethyl) -1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4-on; - forbindelse 20: 5-ethyl-7-(2-piperazin-l-ylpyrimidin-5-yl)- 1.5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 21: 5-ethyl-7-[4-(4-methylpiperazin-l- carbonyl)phenyl]-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 22: 5-ethyl-7-[4-(l-pyrrolidin-l-yl- ethyl)phenyl]-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 23: 7-(4-diethylaminophenyl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 24: 7-(4-amino-2-methylphenyl)-5-ethyl-l,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 25: 7-(4-morpholin-4-ylphenyl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 26: 5-ethyl-7-(4-morpholin-4-ylphenyl)-1,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 27: 5-(5-ethyl-4-oxo-4,5-dihydro-lff-pyrazol [4,3- c]quinolin-7-yl)-2-f luor-AT-methylbenzamid; - forbindelse 28: 5-ethyl-7-(2 — fluor-5-methoxyphenyl)-1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4-on; - forbindelse 29: 7-[3-chlor-4-(morpholin-4-carbonyl)phenyl]- 5-ethyl-l,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 30: 7-[4-(piperazin-l-yl)phenyl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 31: 5-ethyl-7-[2-(4-methylpiperazin-l- yl)pyrimidin-5-yl]-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 32: 7-(4-dimethylaminophenyl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4-on; - forbindelse 33: 2-chlor-4-(5-ethyl-4-oxo-4,5-dihydro-lH- pyrazol[4,3-c]quinolin-7-yl)benzamid; - forbindelse 34: 5-ethyl-7-(lif-indazol-5-yl)-1,5-dihydro-4ii- pyrazol[4,3-c]quinolin-4-on; - forbindelse 35: W-ethyl-3-(5-ethyl-4-oxo-4,5-dihydro-lH- pyrazol[4,3-c]quinolin-7-yl)benzamid; - forbindelse 36: 5-(5-ethyl-4-oxo-4,5-dihydro-lH-pyrazol[4,3- c]quinolin-7-yl)-2-fluorbenzamid; - forbindelse 37: N-(2-dimethylaminoethyl)-3-(5-ethyl-4-oxo- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl)benzamid; - forbindelse 38: N- [4-(5-ethyl-4-oxo-4,5-dihydro-lif- pyrazol[4,3-c]quinolin-7-yl)benzyl]acetamid; - forbindelse 39: 3-(5-ethyl-4-oxo-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl)-N-(2-methoxyethyl)benzamid; - forbindelse 40: 7-(3-hydroxyphenyl)-5-(2,2,2-trifluorethyl)- 1.5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 41: 7-(2-chlor-3-fluorpyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 42: 7-(2-{5-[(propan-2-ylamino)methyl]furan-2- yl}phenyl)-5-(2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3— c]quinolin-4-on; - forbindelse 43: N-[2-(5-ethyl-4-oxo-4,5-dihydro-lH- pyrazol[4,3-c]quinolin-7-yl) phenyl]methansulfonamid; - forbindelse 44: 7-(2-aminophenyl)-5-ethyl-l,5-dihydro-4H- pyrazol[4,3-c]quinolin-4-on; - forbindelse 45: 5-ethyl-7-(3-morpholin-4-ylphenyl)-1,5- dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 46: N-[2-(5-ethyl-4-oxo-4,5-dihydro-lff- pyrazol[4,3-c]quinolin-7-yl)phenyl]acetamid; - forbindelse 47: 5-ethyl-7-(2-hydroxyphenyl)-1,5-dihydro-4H- pyrazol[4,3-c]quinolin-4-on; - forbindelse 48: 5-ethyl-7-[4-(morpholin-4-sulfonyl) phenyl]- 1.5- dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 49: 7-(2-hydroxymethyl-4-methoxyphenyl)-5- (2,2,2-trif luorethyl) -1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4- on; - forbindelse 50: 5-ethyl-7-(3-pyrazol-l-ylphenyl)-1,5- dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 51: 5-ethyl-7-(lH-indol-5-yl)-i, 5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 52: 5-(5-ethyl-4-oxo-4,5-dihydro-lH-pyrazol[4,3- c]quinolin-7-yl)-thiophen-2-carbonitril; - forbindelse 53: 7-(3-chlor-2-hydroxyphenyl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-417-pyrazol [4,3-c] quinolin-4-on; - forbindelse 54: 5-ethyl-7-(2-hydroxy-3-methoxyphenyl)-1,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 55: methyl-3-amino-4-[4-oxo-5-(2,2,2- trifluorethyl) -4,5-dihydro-lli-pyrazol [4,3-c] quinolin-7- yl]benzoat; - forbindelse 56: 5-ethyl-7-(4-methyl-3,4-dihydro-2H- benzo[1,4]oxazin-7-yl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin- 4-on; - forbindelse 57: 7-(2,5-dichlorpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 58: 7-(2-chlor-5-methoxyphenyl)-5-ethyl-l,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 59: N-(3-dimethylaminopropyl)-3-(5-ethyl-4-oxo- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl)benzamid; - forbindelse 60: 5-ethyl-7-(4 — fluor-2-hydroxyphenyl)-1,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 61: 5-ethyl-7-(2 — fluor-4-methoxyphenyl)-1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 62: 7-(4-aminomethylphenyl)-5-ethyl-l,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 63: 5-ethyl-7-(2-fluor-3-methoxyphenyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 64: 7-(2-dimethylaminomethylphenyl)-5-ethyl-l,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 65: 4-(5-ethyl-4-oxo-4,5-dihydro-lH-pyrazol[4,3- c]quinolin-7-yl)benzoesyre; - forbindelse 66: 7-[6-(piperazin-l-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 67: 5-ethyl-7-[6-(piperazin-l-yl)pyrid-3-yl]- 1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 68: 7-[2-(4-methylpiperazin-l-yl)pyrid-4-yl]-5- (2,2,2-trifluorethyl) -1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4- on; - forbindelse 69: 5-ethyl-7-[2-(4-methylpiperazin-l-yl)pyrid- 4-yl] -1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4-on; - forbindelse 70: 7-[2-(piperazin-l-yl)pyrid-4-yl]-5- (2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 71: 5-ethyl-7-(2-piperazin-l-ylpyrid-4-yl)-1, 5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 72: 7-(2-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 73: 5-ethyl-7-(2-methylpyrid-3-yl)-1,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 74: 7-(2-chlor-6-methylpyrid-3-yl)-5-ethyl-l,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 75: 7-(2-chlor-6-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 76: 7-(2-chlorpyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 77: 7-(2-fluorpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 78: 5-ethyl-7-(2-fluorpyrid-3-yl)-1a5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 79: 7-(6-chlor-2-methylpyrid-3-yl)-5-(2,2,2-trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 80: 7-(2-methoxypyrid-3-yl)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 81: 5-ethyl-7-(2-methoxypyrid-3-yl)-1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 82: 7-(6-chlor-4-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 83: 7-[6-(morpholin-4-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 84: 7-[6-(3-dimethylaminopropoxy)pyrid-3-yl]-5- ethyl-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 85: 5-ethyl-7-quinolin-8-yl-l,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 86: 7-(6-chlorpyrid-2-yl)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 87: 5-ethyl-7-quinolin-6-yl-l, 5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 88: 7-(6-chlorpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 89: 7-(6-chlor-5-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 90: 5-ethyl-7-(3-fluorpyrid-4-yl)-1,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 91: 7-(3-chlorpyrid-4-yl)-5-ethyl-l,5-dihydro- 4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 92: 5-ethyl-7-(6-fluor-5-methylpyrid-3-yl)-1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 93: 7-(2-ethoxypyrid-3-yl)-5-ethyl-l,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 94: 5-ethyl-7-(5-methoxypyrid-3-yl)-1,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 95: 7-(6-aminopyrid-3-yl)-5-ethyl-l,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 96: 5-ethyl-7-pyrid-3-yl-2,5-dihydro-4H- pyrazol[4,3-c]quinolin-4-on; - forbindelse 97: 7-(2-chlor-6-isopropylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 98: 7-(5-chlor-2-methoxypyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 99: 7-(pyrid-3-yloxy)-5-(2,2,2-trifluorethyl)- 2.5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 100: 5-ethyl-7-(pyrid-3-yloxy)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 101: 7-(pyrid-3-ylamino)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 102: 5-(2,2-difluorethyl)-7-pyrid-4-yl-l,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 103: 5-cyclopropylmethyl-7-pyrid-4-yl-l,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 104: 5-propyl-7-pyrid-4-yl-l,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 105: 5-(2,2-difluorcyclopropylmethyl)-7-pyrid-4- yl-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 106: 5-(2-fluorethyl)-7-pyrid-4-yl-l,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 107: 5-isopropyl-7-pyrid-4-yl-l, 5-dihydro-4ff- pyrazol[4,3-c]quinolin-4-on; - forbindelse 108: 5-cyclopropyl-7-pyrid-4-yl-l,5-dihydro-4ff- pyrazol[4,3-c]quinolin-4-on; - forbindelse 109: 8-fluor-7-pyrid-2-yl-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 110: 7-(2-chlorpyrid-3-yl)-8-methyl-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 111: 7-(2-chlorpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4fi-pyrazol [4,3-c] quinolin-4-on; - forbindelse 112: 7-[2-(dimethylamino)phenyl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 113: isopropyl-2-[4-oxo-5-(2,2,2-trifluorethyl)- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]benzoat; - forbindelse 114: cyclopropancarboxylsyre-{2-[4-oxo-5- (2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]phenyl}amid; - forbindelse 115: 7-[2-(l-methyl-lii-imidazol-2- carbonyl)phenyl]-5-(2,2,2-trifluorethyl)-1,5-dihydro-4fl-pyrazol[4,3-c]quinolin-4-on; - forbindelse 116: 7-(4-cyclopentylpyrimidin-5-yl)-5-(2,2,2- trif luorethyl) -1,5-dihydro-4fi-pyrazol [4,3-c] quinolin-4-on; - forbindelse 117: 7-(4-cyclohexylpyrimidin-5-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 118: 7-(2-propylaminomethylphenyl)-5- (2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 119: 2-methoxy-77-{2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]phenyl}acetamid; - forbindelse 120: N-{2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]phenyl}isobutyramid; - forbindelse 121: N-{4-methyl-2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lff-pyrazol[4,3-c]quinolin-7- yl]phenyl}propionamid; - forbindelse 122: W-isopropyl-2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]benzamid; - forbindelse 123: 7-[4-methyl-2-(piperidin-4-yloxy)phenyl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4- on; - forbindelse 124: 7-[2-(1,4-diazepan-l-ylmethyl) phenyl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4- on; - forbindelse 125: ethyl-2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]benzoat; - forbindelse 126: 7-(2-aminophenyl)-5-(2,2,2-trifluorethyl)- 2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 127: 7-(2-piperazin-l-ylphenyl)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4fl-pyrazol[4,3-c]quinolin-4-on; - forbindelse 128: 7-(6-methoxypyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 129: 7-(5-chlor-2-fluorpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 130: N-{5-methyl-3-[4-oxo-5-(2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]pyrid-2-yl}acetamid; - forbindelse 131: 7-[2-(2-hydroxy-ethyl)phenyl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 132: 7-(2-amino-5-fluorpyrid-3-yl)-5- (2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 133: 7-[2-(pyrrolidin-l-sulfonyl)phenyl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H -pyrazol[4,3-c]quinolin-4-on; - forbindelse 134: W-isopropyl-2-[4-oxo-5-(2,2,2- trifluorethyl)-4,5-dihydro-lff-pyrazol[4,3-c]quinolin-7- yl]benzensulfonamid; - forbindelse 135: 7-(2-fluor-5-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 136: N,N-diethyl-2-[4-oxo-5-(2,2,2- trifluorethyl)-4,5-dihydro-lff-pyrazol[4,3-c]quinolin-7- yl]benzensulfonamid; - forbindelse 137: 7 -(6-amino-4-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 138: 7-(6-methoxy-2-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4ff-pyrazol [4,3-c] quinolin-4-on; - forbindelse 139: 7-(5-methyl-6-[1,2,4]triazol-4-ylpyrid-3- yl)-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3- c]quinolin-4-on; - forbindelse 140: 7-(4-methyl-6-[1,2,4]triazol-4-ylpyrid-3- yl)-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3- c]quinolin-4-on; - forbindelse 141: 7-[6-(morpholin-4-carbonyl)pyrid-3-yl]-5- (2,2,2-trif luorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quino lin-ion; - forbindelse 142: 7-(6-amino-2-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 143: 7-(4-ethylpyrimidin-5-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 144: methyl-{2-[4-oxo-5-(2,2,2-trifluorethyl)- 4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]phenyl}acetat; - forbindelse 145: 7-(4-methoxypyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 146: 7-(4-propylpyrimidin-5-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 147: N-{6-methyl-5-[4-oxo-5- (2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]pyrid-2-yljpropionamid; - forbindelse 148: 7-(2-oxazol-5-ylphenyl)-5-(2,2,2- triftuoroethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 149: 7-(4-dimethylamino-2-methoxypyrimidin-5- yl)-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3— c]quinolin-4-on; - forbindelse 150: 7-[2-(5-ethyl-[1,2,4]oxadiazol-3- yl)phenyl]-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3— c]quinolin-4-on; - forbindelse 151: N-{2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]benzyl}acetamid; - forbindelse 152: 7-[5-(hydroxyphenylmethyl)pyrid-2-yl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 153: 6-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carbonitril; - forbindelse 154: 7-(6-hydroxymethylpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 155: 7-[3-(2-dimethylaminoethoxy)phenyl]-5- (2,2,2-trif luorethyl) -1,5-dihydro-4if-pyrazol [4,3-c] quinolin-4-on; - forbindelse 156: methyl-2-[4-oxo-5-(2,2,2-trifluorethyl)- 4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]benzoat; - forbindelse 157: 7-(5-hydroxymethylpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 158: 7-(2-methoxypyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 159: 7-(2-[1,2,4]triazol-l-ylmethylphenyl)-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 160: 7-(4-phenylpyrimidin-5-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 161: 7-(6-methoxy-4-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 162: 7-(4-isopropylpyrimidin-5-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 163: 7-(6-fluorpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 164: methyl-6-[4-oxo-5-(2,2,2-trifluorethyl)- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carboxylat; - forbindelse 165: 7-(5-fluorpyrid-2-yl)-5- (2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 166: 7-[2-(4-methylpiperazin-l-yl)pyrid-3-yl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 167: 7-(3-aminopyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 168: 7-(2, 6-dimethylpyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 169: 7-(3-chlorpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 170: methyl-3-[4-oxo-5-(2,2,2-trifluorethyl)- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carboxylat; - forbindelse 171: 7-(6-methylpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 172: 7-[2-(morpholin-4-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 173: 5-(2,2,2-trifluorethyl)-7-(2- trifluormethylpyrid-3-yl)-1,5-dihydro-4H-pyrazol[4,Ιο] quinolin-4-on; - forbindelse 174: 7-(2-cyclopropylaminopyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 175: 5-(2,2,2-trifluorethyl)-7-(3- trifluormethylpyrid-2-yl) -1,5-dihydro-4ii-pyrazol [4,3- c]quinolin-4-on; - forbindelse 176: 3-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carbonitril; - forbindelse 177: 2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-3-carbonitril; - forbindelse 178: methyl-2-[4-oxo-5-(2,2,2-trifluorethyl)- 4.5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]nicotinoat; - forbindelse 179: 7-(2-propoxypyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 180: 7-(3-hydroxypyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 181: 7-[2-(4-fluorphenylamino)pyrid-3-yl]-5- (2,2,2-trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 182: 7-(2-methylaminophenyl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 183: 7-(2-ethoxypyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 184: 7-(2-isopropoxypyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 185: 7-(5-chlor-2-methoxypyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 186: 7-(2-methylpyrid-4-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 187: 7-(4-methylpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 188: 7-(6-morpholin-4-ylpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 189: 7-(4-methylaminophenyl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4fl-pyrazol[4,3-c]quinolin-4-on; - forbindelse 190: 5-(2,2,2-trifluorethyl)-7-(6-trifluormethylpyrid-3-yl)-i, 5-dihydro-4H-pyrazol[4,3— c]quinolin-4-on; - forbindelse 191: 7-(6-methoxypyrid-2-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 192: 7-[4-(2H-tetrazol-5-yl)phenyl]-5-(2,2,2- trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 193: 7-(3, 5-dichlorpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 194: 8-chlor-7-(pyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 195 8-brom-7-pyrid-2-yl-5-(2,2,2-trifluorethyl)- 1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 196: 8-chlor-7-(pyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 197: 8-brom-7-(pyrid-4-yl)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 198: 8-chlor-5-ethyl-7-pyrid-4-yl-l,5-dihydro- 4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 199: 8-chlor-7-(2-chlorpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4#-pyrazol[4,3-c]quinolin-4-on; - forbindelse 200: 8-methyl-7-pyrid-2-yl-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 201: 4-oxo-7-pyrid-4-yl-5-(2,2,2-trifluorethyl)- 4.5- dihydro-2H, 4H-pyrazol[4,3-c]quinolin-8-carbonitril; - forbindelse 202: 4-oxo-7-pyrid-4-yl-5-(2,2,2-trifluorethyl)- 4.5- dihydro-2H, 4ff-pyrazol [4,3-c] quinolin-8-carboxylsyre; - forbindelse 203: 3-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carboxylsyre; - forbindelse 204: 2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]benzoesyre; - forbindelse 205: 4-oxo-7-(pyrid-4-yl)-5-(2,2,2- trifluorethyl)-4,5-dihydro-2H-pyrazol[4,3-c]quinolin-8-carboxamid; - forbindelse 206: 7-[2-(morpholin-4-ylcarbonyl)pyrid-3-yl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 207: N-[2-(dimethylamino)ethyl]-N-methyl-2-[4- oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3— c]quinolin-7-yl]benzamid; - forbindelse 208 : N- (2-dimethylaminoethyl) -iV-ethyl-2-[ 4-oxo- 5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]benzamid; - forbindelse 209: 7-{2-[(4-methyl-l,4-diazepan-l- yl)carbonyl]phenyl}-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 210: 7-{2-[(4-methylpiperazin-l- yl)carbonyl]phenyl}-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 211: N-(3-carbamoylphenyl)-2-[4-oxo-5- (2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]benzamid; - forbindelse 212: N-(3-dimethylaminopropyl)-2-[4-oxo-5- (2,2,2-trif luorethyl) - 4,5-dihydro-lii-pyrazol [4,3-c]quinolin-7-yl]benzamid; - forbindelse 213: N,N-dimethyl-3-[4-oxo-5- (2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carboxamid; - forbindelse 214: 2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]-N-[2-(pyrid-4- yl)ethyl]benzamid; - forbindelse 215: N-[2-(dimethylamino)ethyl]-N-methyl-3-[4- oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lff-pyrazol[4,3— c]quinolin-7-yl]pyridin-2-carboxamid; - forbindelse 216: 7-[2-(1,4-oxazepan-4-ylcarbonyl)pyrid-3- yl]-5-(2,2,2-trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3— c]quinolin-4-on; - forbindelse 217: 77-methyl-3-[ 4-oxo-5- (2,2,2-trif luorethyl) - 4.5- dihydro-lff-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carboxamid; - forbindelse 218: 2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lff-pyrazol [4,3-c] quinolin-7-yl] -77- (pyrid-3- ylmethyl)benzamid; - forbindelse 219: ff-ethyl-2-[4-oxo-5-(2,2,2-trifluorethyl)- 4.5- dihydro-lff-pyrazol[4,3-c]quinolin-7-yl]-N- (pyrid-4-ylmethyl)benzamid; - forbindelse 220: 3-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carboxamid; - forbindelse 221: N- [2-(dimethylamino) ethyl] -T7-ethyl-3-[4- oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3— c]quinolin-7-yl]pyridin-2-carboxamid; - forbindelse 222: 7-[2-((2S, 6R)-2, 6-dimethylmorpholin-4- carbonyl)pyrid-3-yl]-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 223: N-{3-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyrid-2-yl}acetamid; - forbindelse 224: 3-dimethylamino-77- {2-[4-oxo-5- (2,2,2- trifluorethyl)-4,5-dihydro-2H, 4H-pyrazol[4,3-c]quinolin-7- yl]phenyl}propionamid; - forbindelse 225: 4-(dimethylamino)-N- {2-[4-oxo-5-(2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]phenyl}butanamid; - forbindelse 226: 77-{4-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyrid-3-yl}acetamid; - forbindelse 227: N- { 3-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lff-pyrazol[4,3-c]quinolin-7-yl]pyrid-2- yl}cyclopropancarboxamid; - forbindelse 228: 2-methoxy-N- {4-[4-oxo-5-(2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]pyrid-3-yl}-2-phenylacetamid; - forbindelse 229: N-{4-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lff-pyrazol[4,3-c]quinolin-7-yl]pyrid-3-yl}-2-phenylpropionamid; - forbindelse 230: 2-(3-chlorphenyl)-N-{4-[4-oxo-5- (2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]pyrid-3-yl}acetamid; - forbindelse 231: 2-(2,4-dichlorphenyl)-N-{4-[4-oxo-5- (2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]pyrid-3-yl}acetamid; - forbindelse 232: N-{2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-2H-pyrazol[4,3-c]quinolin-7- yl]phenyljmethansulfonamid; - forbindelse 233: 2-(dimethylamino)-N-{2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]phenyl}ethansulfonamid; - forbindelse 234: I7-{2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]phenyl}-1- phenylmethansulfonamid; - forbindelse 235: 3-chlor-iV-{2-[4-oxo-5- (2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]phenyl}benzensu1fonamid; - forbindelse 236: Z7-{4-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyrid-3- yl}methansulfonamid; - forbindelse 237: I7-{4-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyrid-3-yl}-l-phenylmethansulfonamid; - forbindelse 238: 3-chlor-N- {4-[4-oxo-5-(2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]pyrid-3-yl}benzensulfonamid; - forbindelse 239: N-(4-methoxy-3-{4-[4-oxo-5-(2,2,2- trifluorethyl)-4,5-dihydro-lH-pyrazol[4,3-c]quinolin-7- yl]pyrid-3-ylsulfamoyl}benzyl)acetamid; - forbindelse 240: N-{4-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyrid-3-yl} - 2-phenoxybenzensulfonamid; - forbindelse 241: N-methyl-N-{3-[4-oxo-5-(2,2,2- trifluorethyl) -4,5-dihydro-lfi-pyrazol [4,3-c] quinolin-7- yl]pyrid-2-yl}acetamid; - forbindelse 242: AMnethyl-N-{3-[4-oxo-5-(2,2,2- trifluorethyl) -4,5-dihydro-lH-pyrazol [4,3-c] quinolin-7- yl]pyrid-2-yl}cyclopropancarboxamid; - forbindelse 243: 7-[2-(methylamino)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 244: 7-[2-(1,4-diazepan-l-yl)pyrid-3-yl]-5- (2,2,2-trif luorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4- on; - forbindelse 245: 7-(3,4,5, 6-tetrahydro-2H-[1,2']bipyridinyl- 3 ' -yl) -5- (2,2,2-trif luorethyl) -2,5-dihydro-4i7-pyrazol [4,3- c]quinolin-4-on; - forbindelse 246: 7-[2-(3-hydroxypyrrolidin-l-yl)pyrid-3-yl]- 5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 247: 7-[2-(3, 4-dihydroxypyrrolidin-l-yl)pyrid-3- yl]-5-(2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3- c]quinolin-4-on; - forbindelse 248: 7-[2-(dimethylamino)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 249: 7-{2-[ethyl(methyl)amino]pyrid-3-yl}-5- (2,2,2-trif luorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4- on; - forbindelse 250: 7-{2-[(2-hydroxyethyl)(methyl)amino]pyrid- 3-yl}-5-(2,2,2-trifluorethyl)-Ϊ, 5-dihydro-4H-pyrazol[4,3- c]quinolin-4-on; - forbindelse 251: 7-[2-(pyrrolidin-l-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 252: 7-[2-(1,4-oxazepan-4-yl)pyrid-3-yl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 253: 7-[2-(3-oxopiperazin-l-yl)pyrid-3-yl]-5- (2,2,2-trifluorethyl)-1, 5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 254: 7-[2-(azetidin-l-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 255: 7-{2-[(2-methoxyethyl)methylamino]pyrid-3- yl}-5- (2,2,2-trif luorethyl) -2,5-dihydro-4i7-pyrazol [4,3 — c]quinolin-4-on; - forbindelse 256: 7-[2-(4-acetylpiperazin-l-yl)pyrid-3-yl]-5- (2,2,2-trif luorethyl) -2,5-dihydro-4i7-pyrazol [4,3-c]quinolin-4-on; - forbindelse 257: 7-[2-(diethylamino)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3-c]quinolin-4-on; - forbindelse 258: 7-[2-(cyclobutylamino)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 259: 7-[2-(2, 6-dimethylmorpholin-4-yl)pyrid-3- yl]-5-(2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3— c]quinolin-4-on; - forbindelse 260: 7-[2-(4-cyclopropylpiperazin-l-yl)pyrid-4- yl]-5-(2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3- c]quinolin-4-on; - forbindelse 261: 7-(2-cyclohexylaminopyrid-3-yl)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 262: 7-[2-(isopropylmethylamino)pyrid-3-yl]-5- (2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 263: 7-(2-cyclopentylaminopyrid-3-yl)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 264: 7-(6-pyrrolidin-l-ylpyrid-2-yl)-5-(2,2,2- trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 265: 7-[6-(2, 6-dimethylmorpholin-4-yl)pyrid-2- yl] -5-(2,2,2-trifluorethyl) -2,5-dihydro-4H-pyrazol[4,3- c]quinolin-4-on; - forbindelse 266: 7-{2-[cyclohexyl(methyl)amino]pyrid-3-yl}- 5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 267: 7-[2-(4-cyclopropylpiperazin-l-yl)pyrid-3- yl]-5-(2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3- c]quinolin-4-on; - forbindelse 268: 7-[3-(4-cyclopropylpiperazin-l-yl)phenyl]- 5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 269: 7-[2-(4-acetyl-l, 4-diazepan-l-yl)pyrid-3- yl]-5-(2,2,2-trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3— c]quinolin-4-on; - forbindelse 270: 7-[2-(4-methyl-l,4-diazepan-l-yl)pyrid-3-yl]-5-(2,2,2-trifluorethyl)-1,5-dihydro-4ff-pyrazol[4,3- c]quinolin-4-on; - forbindelse 271: 7-[2-(4-cyclopropyl-[1,4]diazepan-1-yl)pyrid-3-yl]-5-(2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 272: 7-[2-(3-fluorpyrrolidin-l-yl)pyrid-3-yl]-5- (2,2,2-trifluorethyl)-2,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 273: 7-[2-(4-fluorpiperidin-l-yl)pyrid-3-yl]-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 274: 7-(2-hydroxypyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4-on; - forbindelse 275: 7-(l-oxypyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 276: 7-(l-oxypyrid-4-yl)-5-(2,2,2- trifluorethyl)-l, 5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; i form af basen eller af et syreadditionssalt og også i hydratform.
6. Forbindelse med formel (I) ifølge et hvilket som helst af ovennævnte krav, der er udvalgt blandt følgende forbindelser: - forbindelse 1: 7-(pyrid-2-yl)-5-(2,2,2-trifluorethyl)-1,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 2: 7-(2-aminopyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 6: 7-(pyrid-4-yl)-5-(2,2,2-trifluorethyl)-1,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 19: 7-[4-(4-methylpiperazin-l-yl)phenyl]-5- (2,2,2-trifluorethyl)-Ϊ, 5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 67: 5-ethyl-7-[6-(piperazin-l-yl)pyrid-3-yl]- 1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 68: 7-[2-(4-methylpiperazin-l-yl)pyrid-4-yl]-5- (2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 69: 5-ethyl-7-[2-(4-methylpiperazin-l-yl)pyrid- 4-yl]-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 72: 7-(2-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4fi-pyrazol [4,3-c] quinolin-4-on; - forbindelse 74: 7-(2-chlor-6-methylpyrid-3-yl)-5-ethyl-l,5- dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 75: 7-(2-chlor-6-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 76: 7-(2-chlorpyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 77: 7-(2-fluorpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4if-pyrazol [4,3-c] quinolin-4-on; - forbindelse 79: 7-(6-chlor-2-methylpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol(4,3-c]quinolin-4-on; - forbindelse 83: 7-[6-(morpholin-4-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 88: 7-(6-chlorpyrid-3-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 111: 7-(2-chlorpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4i7-pyrazol [4,3-c] quinolin-4-on; - forbindelse 168: 7-(2,6-dimethylpyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 169: 7-(3-chlorpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 171: 7-(6-methylpyrid-2-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 172: 7-[2-(morpholin-4-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 176: 3-[4-oxo-5-(2,2,2-trifluorethyl)-4,5- dihydro-lH-pyrazol[4,3-c]quinolin-7-yl]pyridin-2-carbonitril; - forbindelse 186: 7-(2-methylpyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 196: 8-chlor-7-(pyrid-4-yl)-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 199: 8-chlor-7-(2-chlorpyrid-3-yl)-5-(2,2,2- trifluorethyl) -1,5-dihydro-4ii-pyrazol [4,3-c] quinolin-4-on; - forbindelse 209: 7-{2-[(4-methyl-l,4-diazepan-l- yl)carbonyl]phenyl}-5-(2,2,2-trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 232: N-{2-[4-oxo-5-(2,2,2-trifluorethyl)-4,5-dihydro-2H-pyrazol[4,3-c]quinolin-7- yl]phenyl}methansulfonamid; - forbindelse 248: 7-[2-(dimethylamino)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 251: 7-[2-(pyrrolidin-l-yl)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 257: 7-[2-(diethylamino)pyrid-3-yl]-5-(2,2,2- trifluorethyl)-1,5-dihydro-4H-pyrazol[4,3-c]quinolin-4-on; - forbindelse 273: 7-[2-(4-fluorpiperidin-l-yl)pyrid-3-yl]-5- (2,2,2-trifluorethyl) -1,5-dihydro-4H-pyrazol [4,3-c] quinolin-4-on; i form af basen eller af et syreadditionssalt og også i hydratform.
7. Forbindelse med formel (V):
(V) hvori R3 er som defineret i krav 1, og Hal er et halogenatom; i form af basen eller af et syreadditionssalt og også i hydratform.
8. Forbindelse med formel (VI):
(VI) hvori R3 er som defineret i krav 1, Hal er et halogenatom, og PG er en beskyttende gruppe; i form af basen eller af et syreadditionssalt og også i hydratform.
9. Forbindelse med formel (VII):
(VII) (Vil) hvori RI og R3 er som defineret i krav 1, Hal er et halogenatom, og PG er en beskyttende gruppe; i form af basen eller af et syreadditionssalt og også i hydratform.
10. Forbindelse med formel (VIII):
(VIII) hvori RI, R2 og R3 er som defineret i krav 1, og PG er en beskyttende gruppe; i form af basen eller af et syreadditionssalt og også i hydratform.
11. Forbindelse med formel (IX):
(IX) hvori R2 er som defineret i krav 1, R3 er -H, et halogen, -(C1-C6)alkyl, en cyanogruppe eller -CONH2, og PG er en beskyttende gruppe; i form af basen eller af et syreadditionssalt og også i hydratform.
12. Forbindelse med formel (XIV):
(XIV) hvori RI og R3 er som defineret i krav 1, og Hal er et halogenatom; i form af basen eller af et syreadditionssalt og også i hydratform.
13. Forbindelse med formel (XIX):
hvori RI og R3 er som defineret i krav 1, og R er et hydrogenatom, eller begge grupperne R er carbonatomer, der er bundet sammen og eventuelt substitueret med en eller flere grupper (C1-C4) alkyl; i form af basen eller af et syreadditionssalt og også i hydratform.
14. Forbindelse med formel (XX):
hvori RI og R3 er som defineret i krav 1, og R er et hydrogenatom, eller begge grupperne R er carbonatomer, der er bundet sammen og eventuelt substitueret med en eller flere grupper (C1-C4)alkyl, og PG er en beskyttende gruppe; i form af basen eller af et syreadditionssalt og også i hydratform.
DK11306217.8T 2011-09-26 2011-09-26 Pyrazolquinolinonderivater, deres fremstilling og terapeutisk anvendelse deraf DK2573073T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11306217.8A EP2573073B1 (en) 2011-09-26 2011-09-26 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof

Publications (1)

Publication Number Publication Date
DK2573073T3 true DK2573073T3 (da) 2015-01-19

Family

ID=46880738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11306217.8T DK2573073T3 (da) 2011-09-26 2011-09-26 Pyrazolquinolinonderivater, deres fremstilling og terapeutisk anvendelse deraf

Country Status (23)

Country Link
EP (2) EP2573073B1 (da)
JP (1) JP6073328B2 (da)
KR (1) KR20140082743A (da)
CN (1) CN103958479B (da)
AR (1) AR088000A1 (da)
AU (1) AU2012314620B2 (da)
BR (1) BR112014007193A2 (da)
CA (1) CA2847921A1 (da)
CY (1) CY1115945T1 (da)
DK (1) DK2573073T3 (da)
ES (2) ES2527188T3 (da)
HK (1) HK1181763A1 (da)
HR (1) HRP20150024T1 (da)
IL (1) IL231386A (da)
MX (1) MX2014003675A (da)
PL (1) PL2573073T3 (da)
PT (1) PT2573073E (da)
RU (1) RU2621037C2 (da)
SG (1) SG11201400403SA (da)
SI (1) SI2573073T1 (da)
TW (1) TWI527815B (da)
UY (1) UY34350A (da)
WO (1) WO2013045400A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
EP2978764B1 (en) * 2013-03-25 2017-04-19 Sanofi Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)
CA2904820C (en) * 2013-04-05 2021-05-18 Eisai R&D Management Co., Ltd. Pyridinylpyrazoloquinoline compound
WO2014163147A1 (ja) * 2013-04-05 2014-10-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体の塩およびその結晶
GB201406486D0 (en) 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
GB201516616D0 (en) * 2015-09-18 2015-11-04 Redx Pharma Plc Antibacterial compounds
TWI730002B (zh) * 2015-09-18 2021-06-11 日商科研製藥股份有限公司 聯芳系化合物及含有此化合物之醫藥
CN105198888B (zh) * 2015-10-01 2018-03-06 湘潭大学 2,3a‑二取代‑3H–吡唑并[1,5‑a]吲哚‑4(3aH)‑酮衍生物及其合成方法
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
JP6469272B2 (ja) * 2017-03-01 2019-02-13 科研製薬株式会社 ビアリール誘導体又はその塩からなる医薬
CN108721621B (zh) * 2017-04-14 2022-03-01 中国科学院上海高等研究院 抑制肝纤维化的小分子化合物及应用
MX2019013397A (es) 2017-06-01 2020-02-07 Eisai R&D Man Co Ltd Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
EP3632439B1 (en) 2017-06-01 2024-03-27 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
AU2018276568A1 (en) 2017-06-01 2019-11-07 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
RU2656225C1 (ru) * 2017-06-22 2018-06-04 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ получения производных пирроло[2,1-a]изохинолинов
JOP20200001A1 (ar) 2017-07-11 2022-10-30 Vertex Pharma كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
PE20210160A1 (es) 2018-04-25 2021-01-26 Innate Tumor Immunity Inc Moduladores de nlrp3
CN110845478B (zh) * 2019-11-25 2022-07-08 南通大学 含1-取代吡啶基-3-三氟甲基吡唑单元的吡唑甲酰肟衍生物的制备和用途
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
US12077539B2 (en) 2021-03-22 2024-09-03 Incyte Corporation Imidazole and triazole KRAS inhibitors
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンｋｒａｓ阻害剤
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167240B (da) * 1972-06-30 1975-09-27
US3880855A (en) * 1973-04-16 1975-04-29 Bristol Myers Co 5,6-DIHYDRO-11-H-pyrimido{8 4,5-b{9 {8 1,4{9 benzodiazepines
WO2005028474A2 (en) * 2003-05-29 2005-03-31 Millennium Pharmaceuticals, Inc. Pyrazoloquinoline derivatives as chk-1 inhibitors
KR20060117329A (ko) * 2003-11-21 2006-11-16 노파르티스 아게 단백질 키나제 저해제로서의 1ｈ-이미다조퀴놀린 유도체
EP1828180A4 (en) * 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
AU2005324135A1 (en) * 2005-01-07 2006-07-13 Arpida Ag Selected benzofuran derivatives
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
CN103097383B (zh) * 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
DE102010048374A1 (de) * 2010-10-13 2012-04-19 Merck Patent Gmbh Pyrrolidinone als MetAP-2 Inhibitoren
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
AU2012314620A1 (en) 2014-03-27
IL231386A0 (en) 2014-04-30
AR088000A1 (es) 2014-04-30
EP2760841A1 (en) 2014-08-06
RU2621037C2 (ru) 2017-05-31
EP2760841B1 (en) 2016-08-24
CA2847921A1 (en) 2013-04-04
JP2014526545A (ja) 2014-10-06
WO2013045400A1 (en) 2013-04-04
IL231386A (en) 2016-04-21
CN103958479A (zh) 2014-07-30
EP2573073A1 (en) 2013-03-27
JP6073328B2 (ja) 2017-02-01
BR112014007193A2 (pt) 2017-04-04
PL2573073T3 (pl) 2015-04-30
SG11201400403SA (en) 2014-08-28
CY1115945T1 (el) 2017-01-25
ES2527188T3 (es) 2015-01-21
HK1181763A1 (en) 2013-11-15
EP2573073B1 (en) 2014-10-22
TWI527815B (zh) 2016-04-01
KR20140082743A (ko) 2014-07-02
MX2014003675A (es) 2014-08-21
CN103958479B (zh) 2017-06-13
UY34350A (es) 2013-04-30
HRP20150024T1 (hr) 2015-02-13
AU2012314620B2 (en) 2017-06-29
TW201313719A (zh) 2013-04-01
RU2014117035A (ru) 2015-11-10
ES2605152T3 (es) 2017-03-13
PT2573073E (pt) 2015-02-05
SI2573073T1 (sl) 2015-02-27

Similar Documents

Publication Publication Date Title
DK2573073T3 (da) Pyrazolquinolinonderivater, deres fremstilling og terapeutisk anvendelse deraf
JP6042060B2 (ja) ピラゾロキノリノン誘導体、その調製および治療上の使用
US9169246B2 (en) Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
US10472342B2 (en) Compounds and compositions for inhibition of FASN
US8815840B2 (en) Carbazole and carboline kinase inhibitors
CN103012397B (zh) 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
KR101689394B1 (ko) 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 아자인돌 유도체 및 이를 포함하는 약제학적 조성물
JP5350277B2 (ja) Ｐｉ３ｋ阻害剤としてのピロロピリミジン誘導体及びその用途
KR102171710B1 (ko) 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
JP2017518344A (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
US20230150980A1 (en) Collagen 1 translation inhibitors and methods of use thereof
EP2978764B1 (en) Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2)
US20140235616A1 (en) Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
KR20130101408A (ko) 신규한 트리아졸로 피리다진 유도체 및 그의 용도